Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates...
Saved in:
Published in | The Journal of clinical investigation Vol. 104; no. 9; pp. 1277 - 1285 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Clinical Investigation
01.11.1999
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2. |
---|---|
AbstractList | Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2. Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2.Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show here that LIF-induced JAK2 and STAT3 tyrosine phosphorylation is transient, disappearing within 20 and 40 minutes, respectively. LIF activates the SH2 domain-containing tyrosine phosphatase, SHP-1, with maximal stimulation observed at 30 minutes. SHP-1 is constitutively associated with JAK2, and LIF induces recruitment of phosphorylated STAT3 to this complex. Overexpression of wild-type or dominant negative forms of SHP-1 shows decreased or increased LIF-induced proopiomelanocortin (POMC) promoter activity, respectively. LIF-induced JAK2 and STAT3 dephosphorylation is delayed until after 60 minutes in cells that overexpress the mutant SHP-1. In addition, SOCS-3, a negative regulator of LIF signaling, binds to JAK2 after 60 minutes of LIF stimulation, after which the complex is degraded by the proteasome. SOCS-3 overexpression blocks LIF-induced JAK2 tyrosine phosphorylation, confirming a role for SOCS-3 in deactivating JAK2 by direct association. Using SOCS-3 fusion proteins, we also define regions of the SOCS-3 protein that are critical for inhibition of LIF-induced POMC promoter activity. Corticotrophic signaling by LIF is thus subject to 2 forms of negative autoregulation: dephosphorylation of JAK2 and STAT3 by the SHP-1 tyrosine phosphatase, and SOCS-3-dependent inactivation of JAK2. |
Author | Melmed, Shlomo Bousquet, Corinne Susini, Christiane |
AuthorAffiliation | 1 Department of Medicine, Cedars-Sinai Research Institute–University of California–Los Angeles School of Medicine, Los Angeles, California 90048, USA 2 Institut National de la Santé et de la Recherche Médicale (INSERM) U151, Institut Louis Bugnard, 31054 Toulouse, France |
AuthorAffiliation_xml | – name: 1 Department of Medicine, Cedars-Sinai Research Institute–University of California–Los Angeles School of Medicine, Los Angeles, California 90048, USA 2 Institut National de la Santé et de la Recherche Médicale (INSERM) U151, Institut Louis Bugnard, 31054 Toulouse, France |
Author_xml | – sequence: 1 givenname: Corinne surname: Bousquet fullname: Bousquet, Corinne – sequence: 2 givenname: Christiane surname: Susini fullname: Susini, Christiane – sequence: 3 givenname: Shlomo surname: Melmed fullname: Melmed, Shlomo |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10545526$$D View this record in MEDLINE/PubMed |
BookMark | eNplkU1PwzAMhnMAwQaIf4ByglMhH03XHjigiY-hSSANzlGaJhBIk5K0oP17MjHQgJMl-7Ff-_UYbDnvFACHGJ1iPCFnt9PZpCL5FhghRHBWTWi5C8YxviCE85zlO2AXI5YzRooRGGbu2dSm92EJg7cqQu0DXNzcZxgK18DF3XSR0ZS01n8Y9wQ70w-mFwnvgved8a2ywnnpQ28cNK4ZZG-8g_USWjW8qtaIlP3R0EKmuA-2tbBRHazjHni8unyY3mTzu-vZ9GKeyZyiPmMVaxSVSpd1U7KaiILqJteCEYRZIUvZaKy1KFBJhS5JLTFpUKGQ1KRGE0HpHjj_mtsNdasaqVwfhOVdMG26gHth-O-KM8_8yb_zHFUlYan_eN0f_NugYs9bE6Wy6WLlh8iLilBWopXQ0abQj8K30Qk4-QJk8DEGpTcQvnobX78tkdkfUia_V56mDY39x38CW2KedQ |
CitedBy_id | crossref_primary_10_1002_mas_20039 crossref_primary_10_1016_S0167_4889_02_00321_X crossref_primary_10_1016_j_cellsig_2007_07_018 crossref_primary_10_3390_cancers6020897 crossref_primary_10_1074_jbc_M110_161869 crossref_primary_10_3748_wjg_v25_i17_2058 crossref_primary_10_1074_jbc_M401359200 crossref_primary_10_1074_jbc_M003986200 crossref_primary_10_1016_j_cytogfr_2004_06_002 crossref_primary_10_1074_jbc_M505266200 crossref_primary_10_1530_ERC_16_0206 crossref_primary_10_1016_S0169_328X_02_00452_7 crossref_primary_10_1242_dev_00578 crossref_primary_10_1111_j_1471_4159_2008_05759_x crossref_primary_10_1016_S1155_1941_05_38891_3 crossref_primary_10_1172_JCI11182 crossref_primary_10_1007_BF03346713 crossref_primary_10_1046_j_1471_4159_2000_0742021_x crossref_primary_10_2337_diabetes_53_9_2232 crossref_primary_10_1242_jcs_113_16_2813 crossref_primary_10_1002_ijc_27655 crossref_primary_10_1021_acschembio_5b00945 crossref_primary_10_1517_13543776_12_10_1537 crossref_primary_10_1084_jem_194_2_189 crossref_primary_10_1186_s13046_019_1206_z crossref_primary_10_1186_s13148_016_0279_1 crossref_primary_10_1371_journal_ppat_1002229 crossref_primary_10_1530_rep_1_00304 crossref_primary_10_1002_stem_470 crossref_primary_10_1210_endrev_bnac010 crossref_primary_10_1073_pnas_100135197 crossref_primary_10_4049_jimmunol_178_3_1870 crossref_primary_10_1006_phrs_2000_0725 crossref_primary_10_1016_j_jneuroim_2005_08_015 crossref_primary_10_1016_S0014_5793_02_03842_5 crossref_primary_10_1002_jnr_10145 crossref_primary_10_1182_blood_V97_12_3860 crossref_primary_10_1016_S0378_5955_03_00370_8 crossref_primary_10_1016_j_ejcb_2013_03_003 crossref_primary_10_1593_neo_07463 crossref_primary_10_1016_S0006_291X_02_02307_0 crossref_primary_10_1172_JCI200114662 crossref_primary_10_1210_en_2003_0897 crossref_primary_10_1042_CBI20090466 crossref_primary_10_1097_00008469_200608000_00006 crossref_primary_10_1172_JCI200114660 crossref_primary_10_1371_journal_pone_0086330 crossref_primary_10_1002_jnr_20155 crossref_primary_10_1182_blood_V99_7_2351 crossref_primary_10_3390_cancers16030492 crossref_primary_10_1242_jcs_113_23_4331 crossref_primary_10_1158_0008_5472_CAN_04_4359 crossref_primary_10_1016_j_neo_2014_06_005 crossref_primary_10_1113_expphysiol_2006_036236 crossref_primary_10_1038_srep21132 crossref_primary_10_1158_0008_5472_CAN_15_0412 crossref_primary_10_1097_MPA_0000000000000496 crossref_primary_10_3109_08977194_2012_660936 crossref_primary_10_3389_fimmu_2020_00414 crossref_primary_10_1016_j_jmb_2007_12_038 crossref_primary_10_1006_cyto_2001_0887 crossref_primary_10_1016_j_emcend_2005_08_001 crossref_primary_10_1007_BF02981953 crossref_primary_10_1021_jm300207s crossref_primary_10_1089_107999002760274863 crossref_primary_10_1074_jbc_M710462200 crossref_primary_10_1074_jbc_M007373200 crossref_primary_10_1152_ajpendo_00442_2001 |
Cites_doi | 10.1074/jbc.273.12.7099 10.1126/science.7716523 10.1074/jbc.272.16.10551 10.1172/JCI117779 10.1023/A:1009966808106 10.1038/43213 10.1073/pnas.96.12.6964 10.1021/bi00255a030 10.1128/MCB.16.12.6985 10.1016/0168-9525(94)90149-X 10.1128/MCB.15.12.7050 10.1182/blood.V85.1.87.bloodjournal85187 10.1007/BF00202068 10.1074/jbc.273.3.1285 10.1016/S0065-2776(08)60582-9 10.1074/jbc.272.28.17694 10.1016/S1097-2765(00)80062-3 10.1210/endo.139.5.6016 10.1016/S0968-0004(96)10059-1 10.1074/jbc.272.17.11128 10.1016/S0955-0674(97)80067-1 10.1073/pnas.95.22.13130 10.1128/MCB.19.7.4980 10.1101/gad.12.24.3872 10.1210/mend.12.7.0140 10.1002/j.1460-2075.1995.tb00243.x 10.1172/JCI118615 10.1074/jbc.270.31.18179 10.1093/emboj/18.2.375 10.1073/pnas.95.1.114 10.1002/j.1460-2075.1995.tb07281.x 10.1126/science.273.5282.1717 10.1074/jbc.272.37.23376 10.1210/endo.137.7.8770918 10.1074/jbc.274.16.10723 10.1016/0092-8674(95)90351-8 |
ContentType | Journal Article |
Copyright | Copyright © 1999, American Society for Clinical Investigation 1999 |
Copyright_xml | – notice: Copyright © 1999, American Society for Clinical Investigation 1999 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1172/JCI7924 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 1285 |
ExternalDocumentID | PMC409825 10545526 10_1172_JCI7924 |
Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: R01-DK50238 |
GroupedDBID | --- -~X .55 .GJ .XZ 08P 29K 2WC 354 3O- 53G 5GY 5RE 5RS 8F7 AAWTL AAYOK AAYXX ABOCM ABPMR ACGFO ACIHN ACNCT ACPRK ADBBV AEAQA AENEX AFCHL AFFNX AHMBA AI. ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ASPBG AVWKF AZFZN BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EJD EMB F5P FRP GROUPED_DOAJ GX1 HYE H~9 IAO IEA IHR INH IOF IPO J5H KQ8 L7B M1P M5~ MVM N4W OBH OCB ODZKP OFXIZ OGEVE OHH OK1 OVD OVIDX OVT P2P P6G RPM TEORI TR2 TVE UHU VH1 VVN W2D WH7 WOQ WOW X7M XSB YFH YHG YKV YOC ZGI ZXP ZY1 ~H1 08G 36B 3V. 7RV 7X7 88A 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AAKAS ABUWG ADZCM AFKRA BBNVY BCR BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU CGR CUY CVF EBD ECM EIF EMOBN EX3 FEDTE FYUFA HCIFZ HMCUK HVGLF IHW INR IOV ISR ITC LK8 M0L M7P NAPCQ NPM OHT PKN PQQKQ PROAC PSQYO Q2X S0X SJFOW SV3 UKHRP 7X8 5PM |
ID | FETCH-LOGICAL-c430t-595de3cef8bd85b2a63fd4fa520156c8cdf1ffa6083af82bc12d06e0cf2b07a33 |
ISSN | 0021-9738 |
IngestDate | Thu Aug 21 13:44:46 EDT 2025 Fri Jul 11 04:44:41 EDT 2025 Wed Feb 19 01:35:25 EST 2025 Thu Apr 24 22:56:17 EDT 2025 Tue Jul 01 03:48:37 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c430t-595de3cef8bd85b2a63fd4fa520156c8cdf1ffa6083af82bc12d06e0cf2b07a33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Address correspondence to: Shlomo Melmed, Room 2015, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA. Phone: (310) 423-4691; Fax: (310) 423-0119; E-mail: Melmed@CSMC.edu. |
OpenAccessLink | http://www.jci.org/articles/view/7924/files/pdf |
PMID | 10545526 |
PQID | 69235803 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_409825 proquest_miscellaneous_69235803 pubmed_primary_10545526 crossref_primary_10_1172_JCI7924 crossref_citationtrail_10_1172_JCI7924 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1999-11-01 |
PublicationDateYYYYMMDD | 1999-11-01 |
PublicationDate_xml | – month: 11 year: 1999 text: 1999-11-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of clinical investigation |
PublicationTitleAlternate | J Clin Invest |
PublicationYear | 1999 |
Publisher | American Society for Clinical Investigation |
Publisher_xml | – name: American Society for Clinical Investigation |
References | David (B24) 1995; 15 Adams (B16) 1998; 273 Wang (B4) 1996; 137 Bousquet (B5) 1997; 272 Hibi (B1) 1996; 74 Ray (B21) 1996; 97 Klingmuller (B14) 1995; 80 Auernhammer (B19) 1999; 96 Boutillier (B22) 1998; 1 Jiao (B13) 1996; 16 Hackett (B12) 1997; 272 Yetter (B25) 1995; 270 Damen (B26) 1995; 14 Hilton (B15) 1998; 95 You (B10) 1997; 272 Yoshimura (B31) 1995; 14 Ram (B11) 1997; 272 Narazaki (B32) 1998; 95 Kim (B36) 1996; 273 Ihle (B6) 1995; 60 Pei (B28) 1994; 33 Endo (B30) 1997; 387 Bousquet (B20) 1998; 273 Nicholson (B33) 1999; 18 D’Ambrosio (B27) 1995; 268 Kamura (B34) 1998; 12 Akita (B3) 1995; 95 Chesnokova (B2) 1998; 139 Horvath (B7) 1997; 9 Fauman (B9) 1996; 21 Bjorbaek (B17) 1998; 1 Bousquet (B8) 1999; 274 Auernhammer (B18) 1998; 12 Cohney (B35) 1999; 19 Feng (B23) 1994; 10 Yi (B29) 1995; 85 9658400 - Mol Endocrinol. 1998 Jul;12(7):954-61 7629131 - J Biol Chem. 1995 Aug 4;270(31):18179-82 9869640 - Genes Dev. 1998 Dec 15;12(24):3872-81 10196143 - J Biol Chem. 1999 Apr 16;274(16):10723-30 9430658 - J Biol Chem. 1998 Jan 16;273(3):1285-7 9287352 - J Biol Chem. 1997 Sep 12;272(37):23376-81 9889194 - EMBO J. 1999 Jan 15;18(2):375-85 7528537 - Biochemistry. 1994 Dec 27;33(51):15483-93 8521813 - EMBO J. 1995 Nov 15;14(22):5557-68 8191586 - Trends Genet. 1994 Feb;10(2):54-8 7883977 - J Clin Invest. 1995 Mar;95(3):1288-98 9099700 - J Biol Chem. 1997 Apr 18;272(16):10551-7 7796808 - EMBO J. 1995 Jun 15;14(12):2816-26 11081181 - Pituitary. 1998 Apr;1(1):33-43 8621768 - J Clin Invest. 1996 Apr 15;97(8):1852-9 9111009 - J Biol Chem. 1997 Apr 25;272(17):11128-32 9564824 - Endocrinology. 1998 May;139(5):2209-16 10373548 - Mol Cell Biol. 1999 Jul;19(7):4980-8 9507021 - J Biol Chem. 1998 Mar 20;273(12):7099-106 7528577 - Blood. 1995 Jan 1;85(1):87-95 7889566 - Cell. 1995 Mar 10;80(5):729-38 8943354 - Mol Cell Biol. 1996 Dec;16(12):6985-92 9789053 - Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13130-4 8770918 - Endocrinology. 1996 Jul;137(7):2947-53 8524272 - Mol Cell Biol. 1995 Dec;15(12):7050-8 8987394 - Trends Biochem Sci. 1996 Nov;21(11):413-7 7716523 - Science. 1995 Apr 14;268(5208):293-7 10359822 - Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6964-9 9419338 - Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):114-9 9211920 - J Biol Chem. 1997 Jul 11;272(28):17694-702 8834766 - J Mol Med (Berl). 1996 Jan;74(1):1-12 9202126 - Nature. 1997 Jun 26;387(6636):921-4 9660946 - Mol Cell. 1998 Mar;1(4):619-25 8607368 - Adv Immunol. 1995;60:1-35 9069254 - Curr Opin Cell Biol. 1997 Apr;9(2):233-9 8781235 - Science. 1996 Sep 20;273(5282):1717-9 |
References_xml | – volume: 273 start-page: 7099 year: 1998 ident: B20 publication-title: J Biol Chem doi: 10.1074/jbc.273.12.7099 – volume: 268 start-page: 293 year: 1995 ident: B27 publication-title: Science doi: 10.1126/science.7716523 – volume: 272 start-page: 10551 year: 1997 ident: B5 publication-title: J Biol Chem doi: 10.1074/jbc.272.16.10551 – volume: 95 start-page: 1288 year: 1995 ident: B3 publication-title: J Clin Invest doi: 10.1172/JCI117779 – volume: 1 start-page: 33 year: 1998 ident: B22 publication-title: Pituitary doi: 10.1023/A:1009966808106 – volume: 387 start-page: 921 year: 1997 ident: B30 publication-title: Nature doi: 10.1038/43213 – volume: 96 start-page: 6964 year: 1999 ident: B19 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.96.12.6964 – volume: 33 start-page: 15483 year: 1994 ident: B28 publication-title: Biochemistry doi: 10.1021/bi00255a030 – volume: 16 start-page: 6985 year: 1996 ident: B13 publication-title: Mol Cell Biol doi: 10.1128/MCB.16.12.6985 – volume: 10 start-page: 54 year: 1994 ident: B23 publication-title: Trends Genet doi: 10.1016/0168-9525(94)90149-X – volume: 15 start-page: 7050 year: 1995 ident: B24 publication-title: Mol Cell Biol doi: 10.1128/MCB.15.12.7050 – volume: 85 start-page: 87 year: 1995 ident: B29 publication-title: Blood doi: 10.1182/blood.V85.1.87.bloodjournal85187 – volume: 74 start-page: 1 year: 1996 ident: B1 publication-title: J Mol Med doi: 10.1007/BF00202068 – volume: 273 start-page: 1285 year: 1998 ident: B16 publication-title: J Biol Chem doi: 10.1074/jbc.273.3.1285 – volume: 60 start-page: 1 year: 1995 ident: B6 publication-title: Adv Immunol doi: 10.1016/S0065-2776(08)60582-9 – volume: 272 start-page: 17694 year: 1997 ident: B11 publication-title: J Biol Chem doi: 10.1074/jbc.272.28.17694 – volume: 1 start-page: 619 year: 1998 ident: B17 publication-title: Mol Cell doi: 10.1016/S1097-2765(00)80062-3 – volume: 139 start-page: 2209 year: 1998 ident: B2 publication-title: Endocrinology doi: 10.1210/endo.139.5.6016 – volume: 21 start-page: 413 year: 1996 ident: B9 publication-title: Trends Biochem Sci doi: 10.1016/S0968-0004(96)10059-1 – volume: 272 start-page: 11128 year: 1997 ident: B12 publication-title: J Biol Chem doi: 10.1074/jbc.272.17.11128 – volume: 9 start-page: 233 year: 1997 ident: B7 publication-title: Curr Opin Cell Biol doi: 10.1016/S0955-0674(97)80067-1 – volume: 95 start-page: 13130 year: 1998 ident: B32 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.22.13130 – volume: 19 start-page: 4980 year: 1999 ident: B35 publication-title: Mol Cell Biol doi: 10.1128/MCB.19.7.4980 – volume: 12 start-page: 3872 year: 1998 ident: B34 publication-title: Genes Dev doi: 10.1101/gad.12.24.3872 – volume: 12 start-page: 954 year: 1998 ident: B18 publication-title: Mol Endocrinol doi: 10.1210/mend.12.7.0140 – volume: 14 start-page: 5557 year: 1995 ident: B26 publication-title: EMBO J doi: 10.1002/j.1460-2075.1995.tb00243.x – volume: 97 start-page: 1852 year: 1996 ident: B21 publication-title: J Clin Invest doi: 10.1172/JCI118615 – volume: 270 start-page: 18179 year: 1995 ident: B25 publication-title: J Biol Chem doi: 10.1074/jbc.270.31.18179 – volume: 18 start-page: 375 year: 1999 ident: B33 publication-title: EMBO J doi: 10.1093/emboj/18.2.375 – volume: 95 start-page: 114 year: 1998 ident: B15 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.1.114 – volume: 14 start-page: 2816 year: 1995 ident: B31 publication-title: EMBO J doi: 10.1002/j.1460-2075.1995.tb07281.x – volume: 273 start-page: 1717 year: 1996 ident: B36 publication-title: Science doi: 10.1126/science.273.5282.1717 – volume: 272 start-page: 23376 year: 1997 ident: B10 publication-title: J Biol Chem doi: 10.1074/jbc.272.37.23376 – volume: 137 start-page: 2947 year: 1996 ident: B4 publication-title: Endocrinology doi: 10.1210/endo.137.7.8770918 – volume: 274 start-page: 10723 year: 1999 ident: B8 publication-title: J Biol Chem doi: 10.1074/jbc.274.16.10723 – volume: 80 start-page: 729 year: 1995 ident: B14 publication-title: Cell doi: 10.1016/0092-8674(95)90351-8 – reference: 7528577 - Blood. 1995 Jan 1;85(1):87-95 – reference: 9869640 - Genes Dev. 1998 Dec 15;12(24):3872-81 – reference: 7883977 - J Clin Invest. 1995 Mar;95(3):1288-98 – reference: 8191586 - Trends Genet. 1994 Feb;10(2):54-8 – reference: 8524272 - Mol Cell Biol. 1995 Dec;15(12):7050-8 – reference: 8987394 - Trends Biochem Sci. 1996 Nov;21(11):413-7 – reference: 9660946 - Mol Cell. 1998 Mar;1(4):619-25 – reference: 8781235 - Science. 1996 Sep 20;273(5282):1717-9 – reference: 10196143 - J Biol Chem. 1999 Apr 16;274(16):10723-30 – reference: 7629131 - J Biol Chem. 1995 Aug 4;270(31):18179-82 – reference: 8521813 - EMBO J. 1995 Nov 15;14(22):5557-68 – reference: 9658400 - Mol Endocrinol. 1998 Jul;12(7):954-61 – reference: 9564824 - Endocrinology. 1998 May;139(5):2209-16 – reference: 8621768 - J Clin Invest. 1996 Apr 15;97(8):1852-9 – reference: 8834766 - J Mol Med (Berl). 1996 Jan;74(1):1-12 – reference: 9287352 - J Biol Chem. 1997 Sep 12;272(37):23376-81 – reference: 9419338 - Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):114-9 – reference: 9789053 - Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13130-4 – reference: 7716523 - Science. 1995 Apr 14;268(5208):293-7 – reference: 8607368 - Adv Immunol. 1995;60:1-35 – reference: 7796808 - EMBO J. 1995 Jun 15;14(12):2816-26 – reference: 7889566 - Cell. 1995 Mar 10;80(5):729-38 – reference: 9099700 - J Biol Chem. 1997 Apr 18;272(16):10551-7 – reference: 9211920 - J Biol Chem. 1997 Jul 11;272(28):17694-702 – reference: 10373548 - Mol Cell Biol. 1999 Jul;19(7):4980-8 – reference: 9202126 - Nature. 1997 Jun 26;387(6636):921-4 – reference: 8770918 - Endocrinology. 1996 Jul;137(7):2947-53 – reference: 7528537 - Biochemistry. 1994 Dec 27;33(51):15483-93 – reference: 9111009 - J Biol Chem. 1997 Apr 25;272(17):11128-32 – reference: 9430658 - J Biol Chem. 1998 Jan 16;273(3):1285-7 – reference: 8943354 - Mol Cell Biol. 1996 Dec;16(12):6985-92 – reference: 9069254 - Curr Opin Cell Biol. 1997 Apr;9(2):233-9 – reference: 11081181 - Pituitary. 1998 Apr;1(1):33-43 – reference: 10359822 - Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6964-9 – reference: 9507021 - J Biol Chem. 1998 Mar 20;273(12):7099-106 – reference: 9889194 - EMBO J. 1999 Jan 15;18(2):375-85 |
SSID | ssj0014454 |
Score | 1.9324389 |
Snippet | Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that stimulates the hypothalamo-pituitary-adrenal (HPA) axis through JAK-STAT activation. We show... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1277 |
SubjectTerms | Animals Catalysis Cell Line DNA-Binding Proteins - metabolism Down-Regulation Growth Inhibitors - pharmacology Interleukin-6 Intracellular Signaling Peptides and Proteins Janus Kinase 2 Leukemia Inhibitory Factor Lymphokines - pharmacology Mice Models, Biological Phosphorylation Pituitary Gland - metabolism Pro-Opiomelanocortin - metabolism Protein Tyrosine Phosphatase, Non-Receptor Type 11 Protein Tyrosine Phosphatase, Non-Receptor Type 6 Protein Tyrosine Phosphatases - metabolism Protein Tyrosine Phosphatases - physiology Protein-Tyrosine Kinases - metabolism Proteins - physiology Proto-Oncogene Proteins Repressor Proteins SH2 Domain-Containing Protein Tyrosine Phosphatases Signal Transduction STAT3 Transcription Factor Suppressor of Cytokine Signaling 3 Protein Suppressor of Cytokine Signaling Proteins Time Factors Trans-Activators - metabolism Transcription Factors Transfection |
Title | Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10545526 https://www.proquest.com/docview/69235803 https://pubmed.ncbi.nlm.nih.gov/PMC409825 |
Volume | 104 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLbKICEuiJ2y-oC4oEA2O8kRKlA7aACpM9LcqnhTI9JkBIkQXPjrPNupnbYjsVyi1nUW5X19fs_-3meEnksVEVYwFYSCqiBVMQuYEklAYagUOc8ZNfOQJx_p_Cw9Pifnk8mvEWup79gr_vPSupL_sSq0gV11lew_WNZdFBrgM9gXjmBhOP6VjRfNumKVWSbXLEEjrfByOf8cRJaR-Wm2DBJorOv2u6k6r7q-6jRPDvxme6Er7-uyaSEB7SrNeBRWSlaHpLXsv8hNVUKru4fdm2cczvrCMhPSujLLyqt3-GX-t23_DUYhyzPRvD-_or_U9PvKix0AZj0nV9YbOyO7XNftpvXzFEbbIHLzFNu6gSgoMqvl4nyv3Xt4AFkx8qRRPGzvIoevdmefQ4-faQXZ49kiK2wx9q6m9t5Y5xiIJvfJ4tVw4hV0Fe5nc_LFB7cMlaZkkPG2j26rrvWJr4cTd8OZgxxln2o7il1Ob6Ibg4XwG4ugW2gim9vo2slAq7iDeg8kbICEAUjYAAkDkLAFEnZAwg5I-BIgYQckzH7gLZCwBxK2QLqLzt6_O53Ng2E_joCnSdgFpCBCJlyqnImcsLikiRKpKkms6_F5zoWKlCopRPWlymPGo1iEVIYcPECYlUlyDx01bSMfIMwU2JOnnKQlhJRcQtYf5krwvBCJAg8xRS-2r3XFB7F6vWdKvdoz3BRh1_HC6rMcdnm2tcsKfKdeEAMQA-RXtNCF4mEyRfetlUaXgMyCxHSK6I79XAetyr77S1OtjTp7GhZ5TB7--bkeoev-f_IYHXVfe_kEItyOPTUo_A14ELEg |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibitory+roles+for+SHP-1+and+SOCS-3+following+pituitary+proopiomelanocortin+induction+by+leukemia+inhibitory+factor&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Bousquet%2C+Corinne&rft.au=Susini%2C+Christiane&rft.au=Melmed%2C+Shlomo&rft.date=1999-11-01&rft.issn=0021-9738&rft.volume=104&rft.issue=9&rft.spage=1277&rft.epage=1285&rft_id=info:doi/10.1172%2FJCI7924&rft.externalDBID=n%2Fa&rft.externalDocID=10_1172_JCI7924 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon |